Overview:

Summary

The industry analysis specialist, has released its new report, “H1N1 (Swine Influenza) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global H1N1 (Swine Influenza) Therapeutics market. The report identifies the key trends shaping and driving the global H1N1 (Swine Influenza) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global H1N1 (Swine Influenza) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated that the H1N1 (Swine Influenza) therapeutics market to be worth $6.77 billion in 2010. GlobalData expects the H1N1 (Swine Influenza) therapeutics market to decline at a compound annual growth rate (CAGR) of 4% from $6.77 billion in 2010 to $5 billion approximately in 2017. The negative growth is primarily due to the fact that the pandemic has now moved into the post pandemic stage. Moreover the expiration of major drug patents, namely Tamiflu (2016) and Relenza (2013) are also going to put a negative impact on the growth of this market.

Scope

The report provides information on the key drivers and challenges of the H1N1 (Swine Influenza) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) H1N1 (Swine Influenza) Therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as inactivated cell vaccines, Antigenic vaccines, Anti-M2e human antibody, hemagglutinin binder, human rhinovirus inhibitor, T-cell modulator, neuraminidase inhibitors and aganocide compound.
- Analysis of the current and future competition in the seven key countries H1N1 (Swine Influenza) Therapeutics market. Key market players covered are GlaxoSmithKline, Sanofi-Aventis, Novartis, CSL Ltd and Astra Zeneca.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the H1N1 (Swine Influenza) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in H1N1 (Swine Influenza) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global H1N1 (Swine Influenza) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global H1N1 (Swine Influenza) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global H1N1 (Swine Influenza) Therapeutics market landscape? – Identify, understand and capitalize.

Companies Mentioned

Novartis
GlaxoSmithKline plc
Sanofi-Aventis
CSL Limited
AstraZeneca PLC

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 H1N1 (Swine Influenza): Introduction 6
2.1 Overview 6
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 7
2.4 Symptoms 8
2.5 Diagnosis 8
2.6 Treatment and Management Pattern 9
2.7 GlobalData Pipeline Report Guidance 10
3 H1N1 (Swine Influenza): Market Characterization 11
3.1 H1N1 (Swine Influenza) Therapeutics Market Size - Global 11
3.2 H1N1 (Swine Influenza) Therapeutics Market Forecast and CAGR – Global 12
3.3 H1N1 (Swine Influenza) Therapeutics Market Size – the US 13
3.4 H1N1 (Swine Influenza) Therapeutics Market Forecast – the US 14
3.5 H1N1 (Swine Influenza) Therapeutics Market Size – France 15
3.6 H1N1 (Swine Influenza) Therapeutics Market Forecast – France 16
3.7 H1N1 (Swine Influenza) Therapeutics Market Size – Germany 17
3.8 H1N1 (Swine Influenza) Therapeutics Market Forecast – Germany 18
3.9 H1N1 (Swine Influenza) Therapeutics Market Size – Italy 19
3.10 H1N1 (Swine Influenza) Therapeutics Market Forecast – Italy 20
3.11 H1N1 (Swine Influenza) Therapeutics Market Size – Spain 21
3.12 H1N1 (Swine Influenza) Therapeutics Market Forecast – Spain 22
3.13 H1N1 (Swine Influenza) Therapeutics Market Size – the UK 23
3.14 H1N1 (Swine Influenza) Therapeutics Market Forecast – the UK 24
3.15 H1N1 (Swine Influenza) Therapeutics Market Size – Japan 25
3.16 H1N1 (Swine Influenza) Therapeutics Market Forecast – Japan 26
3.17 Drivers and Barriers for the H1N1 (Swine Influenza) Therapeutics Market 27
3.17.1 Drivers of the H1N1 (Swine Influenza) Therapeutics Market 27
3.17.2 Barriers for the H1N1 (Swine Influenza) Therapeutics Market 28
3.18 Opportunity and Unmet Need Analysis 29
3.19 Key Takeaway 30
4 H1N1 (Swine Influenza): Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Major Marketed Product Profiles in the H1N1 (Swine Influenza) Therapeutics Market 32
4.3.1 Fluzone 32
4.3.2 Flumist 32
4.3.3 Fluvirin 33
4.3.4 Afluria 34
4.3.5 Tamiflu 35
4.3.6 Relenza 36
4.3.7 Laninamivir 37
4.4 Key Takeaway 38
5 H1N1 (Swine Influenza) Therapeutics: Pipeline Assessment 39
5.1 Overview 39
5.2 Strategic Pipeline Assessment 39
5.3 H1N1 (Swine Influenza) Therapeutics Pipeline – Pipeline by Clinical Phases of Development 39
5.3.1 H1N1 (Swine Influenza) Therapeutics – Phase III Clinical Pipeline 40
5.3.2 H1N1 (Swine Influenza) Therapeutics – Phase II Clinical Pipeline 40
5.3.3 H1N1 (Swine Influenza) Therapeutics – Phase I Clinical Pipeline 40
5.3.4 H1N1 (Swine Influenza) – Preclinical Pipeline 41
5.3.5 H1N1 (Swine Influenza) – Discovery Clinical Pipeline 41
5.4 H1N1 (Swine Influenza) Therapeutics – Pipeline by Mechanism of Action 42
5.5 Technology Trends Analytic Framework 43
5.6 H1N1 (Swine Influenza) Therapeutics – Most Promising Drugs under Clinical Development 45
5.7 Most Promising Drugs Profile 46
5.7.1 Humenza 46
5.7.2 MF59-eH5N1 Influenza Vaccine 46
5.7.3 Peramivir 47
5.8 Key Takeaway 48
6 H1N1 (Swine Influenza) Therapeutics: Clinical Trials Mapping 49
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 49
6.2 Clinical Trials by Phase of Clinical Development 50
6.3 Clinical Trials by Trial Status 51
6.4 Prominent Sponsors 52
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 53
7 H1N1 (Swine Influenza) Therapeutics: Strategic Assessment 53
7.1 Key Events impacting the Future Market 53
7.2 Future Market Competition Scenario 54
8 H1N1 (Swine Influenza) Therapeutics: Future Players 56
8.1 Introduction 56
8.2 Novartis 56
8.2.1 Company Overview 56
8.2.2 Financial Overview 57
8.2.3 Business Description 57
8.2.4 Deals, Alliances and Partnerships 59
8.2.5 Influenza Vaccines Pipeline 60
8.3 GlaxoSmithKline plc 60
8.3.1 Overview 60
8.3.2 Financial Overview 60
8.3.3 Business Overview 60
8.3.4 Deals, Alliances and Partnerships 61
8.3.5 Influenza Vaccines Pipeline 65
8.4 Sanofi-Aventis 66
8.4.1 Company Overview 66
8.4.2 Financial Overview 66
8.4.3 Business Description 66
8.4.4 Deals, Alliances and Partnerships 68
8.4.5 Infectious Diseases Vaccines Pipeline 69
8.5 CSL Limited 70
8.5.1 Company Overview 70
8.5.2 Financial Overview 70
8.5.3 Business Description 70
8.5.4 Deals, Alliances and Partnerships 72
8.5.5 Influenza Vaccines Pipeline 72
8.6 AstraZeneca PLC 73
8.6.1 Overview 73
8.6.2 Financial Overview 73
8.6.3 Business Overview 73
8.6.4 Deals, Alliances and Partnerships 75
8.6.5 Pipeline Products 76
8.7 Other Companies in the H1N1 (Swine Influenza) Therapeutics Market 77
9 H1N1 (Swine Influenza) Therapeutics Market: Licencing and Partnership Deals 80
10 H1N1 (Swine Influenza) Therapeutics Market: Appendix 81
10.1 Definitions 81
10.2 Abbreviations 81
10.3 Research Methodology 82
10.3.1 Coverage 82
10.3.2 Secondary Research 83
10.3.3 Forecasting 83
10.3.4 Primary Research 86
10.3.5 Expert Panels 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Sources 87

1.1 List of Tables
Table 1: Estimated Number of H1N1 Deaths in 2010 7
Table 2: H1N1 (Swine Influenza) Therapeutics Market, Global, Revenue ($m), 2005–2010 11
Table 3: H1N1 (Swine Influenza) Therapeutics Market, Global, Forecast ($m), 2010–2017 12
Table 4: H1N1 (Swine Influenza) Therapeutics Market, the US, Revenue ($m), 2005–2010 13
Table 5: H1N1 (Swine Influenza) Therapeutics Market, the US, Forecast ($m), 2010–2017 14
Table 6: H1N1 (Swine Influenza) Therapeutics Market, France, Revenue ($m), 2005–2010 15
Table 7: H1N1 (Swine Influenza) Therapeutics Market, France, Forecast ($m), 2010–2017 16
Table 8: H1N1 (Swine Influenza) Therapeutics Market, Germany, Revenue ($m), 2005–2010 17
Table 9: H1N1 (Swine Influenza) Therapeutics Market, Germany, Forecast ($m), 2010–2017 18
Table 10: H1N1 (Swine Influenza) Therapeutics Market, Italy, Revenue ($m), 2005–2010 19
Table 11: H1N1 (Swine Influenza) Therapeutics Market, Italy, Forecast ($m), 2010–2017 20
Table 12: H1N1 (Swine Influenza) Therapeutics Market, Spain, Revenue ($m), 2005–2010 21
Table 13: H1N1 (Swine Influenza) Therapeutics Market, Spain, Forecast ($m), 2010–2017 22
Table 14: H1N1 (Swine Influenza) Therapeutics Market, the UK, Revenue ($m), 2005–2010 23
Table 15: H1N1 (Swine Influenza) Therapeutics Market, the UK, Forecast ($m), 2010–2017 24
Table 16: H1N1 (Swine Influenza) Therapeutics Market, Japan, Revenue ($m), 2005–2010 25
Table 17: H1N1 (Swine Influenza) Therapeutics Market, Japan, Forecast ($m), 2010–2017 26
Table 18: Major Marketed Product in the H1N1(Swine Influenza) Therapeutics Market, 2010 38
Table 19: H1N1 (Swine Influenza) Therapeutics, Phase III Pipeline, 2010 40
Table 20: H1N1 (Swine Influenza) Therapeutics, Phase II Pipeline, 2010 40
Table 21: H1N1 (Swine Influenza) Therapeutics, Phase I Pipeline, 2010 40
Table 22: H1N1 (Swine Influenza) Therapeutics, Preclinical Pipeline, 2010 41
Table 23: H1N1 (Swine Influenza) Therapeutics, Discovery Clinical Pipeline, 2010 41
Table 24: H1N1 Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010 45
Table 25: H1N1 (Swine Influenza) Therapeutics Market, Global, Clinical Trials, 2010 49
Table 26: H1N1 (Swine Influenza) Therapeutics, Global, Clinical Trials by Phase, 2010 50
Table 27: H1N1 (Swine Influenza) Therapeutics, Global, Clinical Trials by Status of Development, 2010 51
Table 28: H1N1 (Swine Influenza) Therapeutics, Global, Prominent Sponsors, 2010 52
Table 29: H1N1 (Swine Influenza) Therapeutics Market, Global, Top 10 Companies by Phase, 2010 53
Table 30: Novartis, Deals, Alliances and Partnerships 59
Table 31: Novartis, Influenza Vaccines Pipeline, 2010 60
Table 32: GlaxoSmithKline, Deals, Alliances and Partnerships 61
Table 33: GlaxoSmithKline, Influenza Vaccines Pipeline, 2010 65
Table 34: Sanofi Aventis, Deals, Alliances and Partnerships 68
Table 35: Sanofi-Aventis, Influenza Vaccines Pipeline, 2010 69
Table 36: CSL Limited, Deals, Alliances and Partnerships 72
Table 37: CSL Limited, Influenza Vaccines Pipeline, 2010 72
Table 38: Astra Zeneca, Deals, Alliances and Partnerships 75
Table 39: Astra Zeneca, Influenza Vaccines Pipeline, 2010 76
Table 40: H1N1 (Swine Influenza) Therapeutics market, Future Players, 2010 77
Table 41: H1N1 (Swine Influenza) Therapeutics market, Global, Deals, 2010 80

1.2 List of Figures
Figure 1: H1N1 Swine Influenza Therapeutics Market, Global, Pandemic Influenza Phases 6
Figure 2: H1N1 (Swine Influenza) Therapeutics Market, Global, Revenue ($m), 2005–2010 11
Figure 3: H1N1 (Swine Influenza) Therapeutics Market, Global, Forecast ($m), 2010–2017 12
Figure 4: H1N1 (Swine Influenza) Therapeutics Market, the US, Revenue ($m), 2005–2010 13
Figure 5: H1N1 (Swine Influenza) Therapeutics Market, the US, Forecast ($m), 2010–2017 14
Figure 6: H1N1 (Swine Influenza) Therapeutics Market, France, Revenue ($m), 2005–2010 15
Figure 7: H1N1 (Swine Influenza) Therapeutics Market, France, Forecast ($m), 2010–2017 16
Figure 8: H1N1 (Swine Influenza) Therapeutics Market, Germany, Revenue ($m), 2005–2010 17
Figure 9: H1N1 (Swine Influenza) Therapeutics Market, Germany, Forecast ($m), 2010–2017 18
Figure 10: H1N1 (Swine Influenza) Therapeutics Market, Italy, Revenue ($m), 2005–2010 19
Figure 11: H1N1 (Swine Influenza) Therapeutics Market, Italy, Forecast ($m), 2010–2017 20
Figure 12: H1N1 (Swine Influenza) Therapeutics Market, Spain, Revenue ($m), 2005–2010 21
Figure 13: H1N1 (Swine Influenza) Therapeutics Market, Spain, Forecast ($m), 2010–2017 22
Figure 14: H1N1 (Swine Influenza) Therapeutics Market, the UK, Revenue ($m), 2005–2010 23
Figure 15: H1N1 (Swine Influenza) Therapeutics Market, the UK, Forecast ($m), 2010–2017 24
Figure 16: H1N1 (Swine Influenza) Therapeutics Market, Japan, Revenue ($m), 2005–2010 25
Figure 17: H1N1 (Swine Influenza) Therapeutics Market, Japan, Forecast ($m), 2010–2017 26
Figure 18: Opportunity and Unmet Need in the H1N1 (Swine Influenza) Market, 2010 29
Figure 19: Strategic Competitor Assessment of the Major Marketed Products in H1N1 Treatment, 2010 31
Figure 20: H1N1 Swine Influenza Therapeutics, Pipeline by Phases of Development (%), 2010 39
Figure 21: H1N1 (Swine Influenza) Therapeutics Market, Pipeline by Mechanism of Action (%), 2010 42
Figure 22: Technology Trends Analytic Framework of the H1N1 Therapeutics Pipeline, Vaccines, 2010 43
Figure 23: Technology Trends Analytic Framework of the H1N1 Therapeutics Pipeline, Vaccines, Description, 2010 43
Figure 24: Technology Trends Analytic Framework of the H1N1 Therapeutics Pipeline, Drugs (Antivirals), 2010 44
Figure 25: Technology Trends Analytic Framework of the H1N1 Therapeutics Pipeline, Drugs (Antivirals), Description, 2010 45
Figure 26: H1N1 (Swine Influenza) Therapeutics Market, Global, Clinical Trials by Country, 2010 49
Figure 27: H1N1 (Swine Influenza) Therapeutics, Global, Clinical Trials by Phase (%), 2010 50
Figure 28: H1N1 (Swine Influenza) Therapeutics, Global, Clinical Trials by Status of Development (%), 2010 51
Figure 29: H1N1 (Swine Influenza) Therapeutics, Global, Prominent Sponsors (%), 2010 52
Figure 30: H1N1 (Swine Influenza) Therapeutics Market, Global, Top 10 Companies by Phase, 2010 53
Figure 31: H1N1 (Swine Influenza) Therapeutics Market, Global, Key Events impacting the Future Market, 2010 53
Figure 32: H1N1 (Swine Influenza) Therapeutics Market, Implications for Future Market Competition, 2010 54
Figure 33: H1N1 (Swine Influenza) Therapeutics, Clinical Pipeline by Company, 2010 56
Figure 34: GlobalData Market Forecasting Model 85